GANX - Twist Bioscience and Codexis in focus as Piper Sandler upbeat on synthetic biology and more in today's analyst action

Piper Sandler paints an upbeat outlook for the synthetic biology (SynBio) space as the firm initiates coverage on Codexis (CDXS) and Twist Biosciences (TWST).Twist Bioscience and Codexis in focus as Piper Sandler sizes up synthetic biologyThe analyst Steven Mah predict the global market for synthetic biology to reach ~$1.2B including an estimated total addressable market of $270B for SynBio in the U.S.Twist Bioscience (TWST) gets a price target of $150.00 per share implying ~13.4% upside to the previous close.The DNA writing platform of the company is ‘customizable, highly scalable, low-cost and applicable across multiple industries, including biopharma discovery,’ the analyst noted.Cathie Wood’s ARK Investment Management is a top holder in Twist which was downgraded by JPMorgan in February.Codexis enzyme engineering platform in focusCodexis (CDXS) is up ~3.0% in the pre-market after an overweight rating from Piper Sandler. The price target of $32.00 per share implies ~33.3% upside to the previous

For further details see:

Twist Bioscience and Codexis in focus as Piper Sandler upbeat on synthetic biology, and more in today’s analyst action